6 results on '"Çapar S"'
Search Results
2. Inhibiting Stat Signaling Pathways as a Possible Therapy to Modulate Synovial Inflammation in Osteoarthritis
- Author
-
Suijkerbuijk, M.A., primary, Çapar, S., additional, Kops, N., additional, Meuffels, D.E., additional, van Osch, G.J., additional, and Bastiaansen-Jenniskens, Y.M., additional
- Published
- 2017
- Full Text
- View/download PDF
3. A real-life analysis of patients with rheumatologic diseases on biological treatments: Data from TURKBIO Registry
- Author
-
Fatoş, Önen, Gerçek, Can, Sedat, Çapar, Ediz, Dalkılıç, Yavuz, Pehlivan, Soner, Şenel, Servet, Akar, Süleyman Serdar, Koca, Abdurrahman, Tufan, Ayten, Yazıcı, Sema, Yılmaz, Nevsun, İnanç, İsmail, Sarı, Merih, Birlik, Dilek, Solmaz, Ayşe, Cefle, Mehmet Akif, Öztürk, Servet, Yolbaş, Niels Steen, Krogh, Neslihan, Yılmaz, Şükran, Erten, Cemal, Bes, Özgül Soysal, Gündüz, Berna, Göker, Seminur, Haznedaroğlu, Şule, Yavuz, Gözde, Yildirim Çetin, Fatih, Yıldız, Haner, Direskeneli, Nurullah, Akkoç, and Önen F., Can G., Çapar S., Dalkılıç E., Pehlivan Y., Şenel S., Akar S., Koca S. S., Tufan A., Yazıcı A., et al.
- Subjects
RHEUMATOLOGY ,IZMIR ,Klinik Tıp ,Turkey ,ARTHRITIS PATIENTS ,TIGHT CONTROL ,CLINICAL MEDICINE ,EFFICACY ,Clinical Medicine (MED) ,PREVALENCE ,Biologic registry ,Klinik Tıp (MED) ,AXIAL SPONDYLOARTHRITIS ,ROMATOLOJİ ,rheumatic disease - Abstract
Objective: TURKBIO registry, established in 2011, is the first nationwide biological database in Turkey. This study aimed to provide an overview of TURKBIO data collected by June 2018. Methods: The registry included adult patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), nonradiographic axial spondyloarthritis (nr-AxSpA), and psoriatic arthritis (PsA). Demographic and clinical features, disease activity markers, and other follow-up parameters, current and previous treatments, and adverse events were registered electronically at each visit using open-source software. The registration of patient-reported outcome measures was carried out electronically by the patients using touch screens. Results: TURKBIO registry included a total of 41,145 treatment series with biologicals. There were 2,588 patients with axSpA (2,459 AS and 129 nr-axSpA), 2,036 with RA, and 428 with PsA. The total number of patients, including those with other diagnoses, was 5,718. In the follow-up period, the number of patients and also visits steadily increased by years. The yearly mean number of visits per patient was found to be 2.3. Significant improvements in disease activity and health assessment parameters were observed following the biological treatments. Biologics were often given in combination with a conventional synthetic disease-modifying antirheumatic drug in patients with RA. Infections were the most commonly seen adverse events, followed by allergic reactions. Tuberculosis was observed in 12 patients, malignancy in 18, and treatment-related mortality in 31. Conclusion: TURKBIO provided a valuable real-life experience with the use of biologics in rheumatic diseases in Turkey
- Published
- 2022
4. The impact of smoking on response to tumor necrosis factor-α inhibitor treatment in patients with ankylosing spondylitis.
- Author
-
Tuğsal HY, Artin GK, Can G, Çapar S, Zengin B, Akar S, Dalkiliç HE, Şenel AS, Koca SS, Göker B, Yazici A, İnanç GN, Ellidokuz H, Akkoç N, and Önen F
- Subjects
- Humans, Male, Adult, Female, Tumor Necrosis Factor-alpha, Treatment Outcome, Smoking epidemiology, Immunologic Factors therapeutic use, Severity of Illness Index, Spondylitis, Ankylosing drug therapy, Antirheumatic Agents therapeutic use
- Abstract
Background: To investigate the impact of smoking on disease activity, treatment retention, and response in patients with ankylosing spondylitis (AS) treated with their first tumor necrosis factor-α inhibitor (TNFi)., Methods: AS patients who started their first TNFi treatment for the active axial disease (BASDAI ≥ 4) from TURKBIO Registry were included. Treatment response of smoker (current and ex-smokers) and nonsmoker (never smoker) patients were primarily evaluated as achievement of BASDAI50 or improvement in BASDAI at least 20 mm at 3 months and 6 months compared to baseline., Results: There were 322 patients with AS (60% male, 59% smoker, mean age: 38.3 years). The median follow-up time was 2.8 years (Q1- Q3: 1.3-3.8), and disease duration was 3.5 years (Q1-Q3: 0.7-8.2). Smokers had male predominance (p < 0.001), lower ESR (p = 0.03), higher BASDAI (p = 0.02), BASFI (p = 0.05), HAQ-AS (p = 0.007), and ASDAS-CRP (p = 0.04) compared with nonsmokers at baseline. In the multivariate analysis, male gender [OR 2.7 (95%CI 1.4-5), p = 0.002], and concomitant conventional synthetic disease-modifying antirheumatic drug use [OR 2.4 (95%CI 1.1-5.2), p = 0.03] were associated with better treatment response. There was an association of male gender [HR 2.4 (95%CI 1.6-3.7), p < 0.001], older age (≥30years) [HR 1.8 (95%CI 1.1-2.8), p = 0.01], and response to treatment [HR 1.8 (95%CI 1.2-2.9), p = 0.008] with better treatment retention. No impact of smoking status was found on treatment retention and response in univariate and multivariate analyses., Discussion: This study suggested that smoking was associated with poorer patient-reported outcomes in biologic naïve AS patients initiating their first TNFi treatment, but it had no impact on the TNFi treatment response and retention rate.
- Published
- 2023
- Full Text
- View/download PDF
5. A real-life analysis of patients with rheumatologic diseases on biological treatments: Data from TURKBIO Registry.
- Author
-
Önen F, Can G, Çapar S, Dalkılıç E, Pehlivan Y, Şenel S, Akar S, Koca SS, Tufan A, Yazıcı A, Yılmaz S, İnanç N, Sarı İ, Birlik M, Solmaz D, Cefle A, Öztürk MA, Yolbaş S, Krogh NS, Yılmaz N, Erten Ş, Bes C, Gündüz ÖS, Göker B, Haznedaroğlu S, Yavuz Ş, Yildirim Çetin G, Yıldız F, Direskeneli H, and Akkoç N
- Abstract
Objective: TURKBIO registry, established in 2011, is the first nationwide biological database in Turkey. This study aimed to provide an overview of TURKBIO data collected by June 2018., Methods: The registry included adult patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), nonradiographic axial spondyloarthritis (nr-AxSpA), and psoriatic arthritis (PsA). Demographic and clinical features, disease activity markers, and other follow-up parameters, current and previous treat- ments, and adverse events were registered electronically at each visit using open-source software. The registration of patient-reported outcome measures was carried out electronically by the patients using touch screens., Results: TURKBIO registry included a total of 41,145 treatment series with biologicals. There were 2,588 patients with axSpA (2,459 AS and 129 nr-axSpA), 2,036 with RA, and 428 with PsA. The total number of patients, including those with other diagnoses, was 5,718. In the follow-up period, the number of patients and also visits steadily increased by years. The yearly mean number of visits per patient was found to be 2.3. Significant improvements in disease activity and health assessment parameters were observed following the biological treatments. Biologics were often given in combination with a con- ventional synthetic disease-modifying antirheumatic drug in patients with RA. Infections were the most commonly seen adverse events, followed by allergic reactions. Tuberculosis was observed in 12 patients, malignancy in 18, and treatment-related mortality in 31., Conclusion: TURKBIO provided a valuable real-life experience with the use of biologics in rheumatic diseases in Turkey.
- Published
- 2022
- Full Text
- View/download PDF
6. Morphology and morphometry of Bresslauides pratensis n. sp., a new soil ciliate (Ciliophora, Colpodea) from Turkey.
- Author
-
Çapar S
- Subjects
- Biometry, Ciliophora isolation & purification, Microscopy, Electron, Organelles ultrastructure, Soil parasitology, Turkey, Ciliophora classification, Ciliophora ultrastructure
- Abstract
A new colpodid ciliate, Bresslauides pratensis n. sp., was discovered in soil from a meadow field in Turkey. Its morphology was investigated using live observation, protargol impregnation, silver nitrate impregnation, and scanning electron microscopy. The new species differs from the congeners by the following combination of features: the cell size in vivo is about 135-180 μm × 130-160 μm; the body has an almost circular outline with a conspicuous bulge on the ventral side; the somatic cilia are arranged in about 105 densely spaced, sigmoidal kineties; a diagonal groove extends to the left cell side, terminating in a pronounced postoral sack; one almost globular macronucleus and usually two globular micronuclei; the oral structures occupy almost the anterior half of the cell and comprise a distally elongated right polykinetid and a crescentic left oral polykinetid, both restricted to the vestibulum; on average 12 vestibular, 31 postoral, and 55 left oral kineties. Based on the morphological data, it was concluded that B. pratensis is a well-outlined and distinctive member of the genus Bresslauides. Additionally, the most recent molecular data on the order Colpodida and genera Colpoda, Bresslaua, and Bresslauides are briefly discussed., (Copyright © 2012 Elsevier GmbH. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.